To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome

ClinicalTrials.gov ID: NCT06840496

Public ClinicalTrials.gov record NCT06840496. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Bionetide for the Treatment of Girls and Women With Rett Syndrome

Study identification

NCT ID: NCT06840496
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Biomed Industries, Inc.; Industry
Enrollment: 210 participants

Conditions and interventions

Conditions

Rett Syndrome

Interventions

Bionetide Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 5 Years to 20 Years
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 29, 2026
Primary completion: Sep 29, 2027
Completion: Dec 29, 2027
Last update posted: Mar 26, 2026

2026 – 2027

United States locations

U.S. sites: 14
U.S. states: 11
U.S. cities: 14

Facility	City	State	ZIP	Site status
Biomed Testing Facility # BIO-01-85012	Phoenix	Arizona	85012	Recruiting
Biomed Testing Facility # BIO-05-92093	La Jolla	California	92093	Recruiting
Biomed Testing Facility # BIO-04-90095	Los Angeles	California	90045	Recruiting
Biomed Testing Facility # BIO-03-95817	Sacramento	California	95817	Recruiting
Biomed Testing Facility # BIO-02-94104	San Francisco	California	94104	Recruiting
Biomed Testing Facility #BIO-06-80042	Aurora	Colorado	80042	Recruiting
Biomed Testing Facility #BIO-07-33606	Tampa	Florida	33606	Recruiting
Biomed Testing Facility #BIO-08-60612	Chicago	Illinois	60612	Recruiting
Maryland Locations Biomed Testing Facility #BIO-9-21205	Baltimore	Maryland	21205	Recruiting
Biomed Testing Facility #BIO-10-02115	Boston	Massachusetts	02115	Recruiting
Biomed Testing Facility #BIO-13-10467	The Bronx	New York	10467	Recruiting
Biomed Testing Facility #BIO-17-19104	Philadelphia	Pennsylvania	19104	Recruiting
Biomed Testing Facility #BIO-19-77030	Houston	Texas	77030	Recruiting
Biomed Testing Facility #BIO-20-98105	Seattle	Washington	98105	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06840496, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 26, 2026 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06840496 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →